Abeona Therapeutics Inc. (LON:0H7R)
London flag London · Delayed Price · Currency is GBP · Price in USD
4.969
-0.060 (-1.19%)
Feb 12, 2026, 4:51 PM GMT

Abeona Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
0.4-3.51.41310
Revenue Growth (YoY)
--147.53%-52.87%-70.00%-
Cost of Revenue
29.6834.3632.729.4238.7330.14
Gross Profit
-29.28-34.36-29.2-28-35.73-20.14
Selling, General & Admin
53.9329.851917.2621.6423.78
Operating Expenses
53.9329.851917.2621.6428.37
Operating Income
-83.21-64.21-48.2-45.26-57.37-48.5
Interest Expense
-3.94-4.21-0.42-0.74-3.66-4.12
Interest & Investment Income
5.034.252.120.430.041.3
Other Non Operating Income (Expenses)
12.410.44-8.7111.660.02-
EBT Excluding Unusual Items
-69.7-63.74-55.21-33.9-60.97-51.32
Impairment of Goodwill
-----32.47-
Gain (Loss) on Sale of Assets
152.370-0.05-0.14--
Asset Writedown
--1.07-5.66--32.92
Other Unusual Items
----8.5-
Pretax Income
82.67-63.73-54.19-39.7-84.94-84.23
Net Income
82.35-63.73-54.19-39.7-84.94-84.23
Preferred Dividends & Other Adjustments
---3.78--
Net Income to Common
82.35-63.73-54.19-43.48-84.94-84.23
Shares Outstanding (Basic)
514121844
Shares Outstanding (Diluted)
624121844
Shares Change (YoY)
74.23%91.99%171.96%99.65%6.24%84.02%
EPS (Basic)
1.60-1.55-2.53-5.53-21.57-22.73
EPS (Diluted)
1.29-1.55-2.53-5.53-21.57-22.73
Free Cash Flow
-82.36-58.46-37.34-43.61-69.82-36.36
Free Cash Flow Per Share
-1.34-1.42-1.75-5.55-17.73-9.81
Gross Margin
------201.39%
Operating Margin
-20802.25%--1377.14%-3200.64%-1912.33%-485.04%
Profit Margin
20587.50%--1548.23%-3074.82%-2831.20%-842.34%
Free Cash Flow Margin
-20590.00%--1066.86%-3084.37%-2327.20%-363.55%
EBITDA
-80.98-62.21-45.91-42.16-54.12-43.92
D&A For EBITDA
2.2322.293.093.254.59
EBIT
-83.21-64.21-48.2-45.26-57.37-48.5
Revenue as Reported
-----10
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.